Lite Strategy (LITS) Net Income (2010 - 2026)
Lite Strategy (LITS) posted Net Income of -$21.6 million for Q1 2026, up 27.68% on a QoQ basis from -$29.8 million in Q4 2025, and down 738.1% year-over-year from $3.4 million in Q1 2025.
Analysis
Lite Strategy (LITS) Net Income (2010 - 2026) Analysis & Trends
Lite Strategy has reported Net Income for 17 years, with the latest figure at -$21.6 million in Q1 2026.
- On a quarterly basis, Net Income fell 738.1% year-over-year to -$21.6 million in Q1 2026; TTM through Mar 2026 was -$57.7 million, a 79.65% decrease from a year earlier, with the FY2025 full-year figure at -$16.4 million, down 192.2% from the prior year.
- Net Income was -$21.6 million for Q1 2026 at Lite Strategy, up from -$29.8 million in the prior quarter.
- The five-year high for Net Income was $56.4 million in Q3 2023, with the low at -$29.8 million in Q4 2025.
- Average Net Income over 5 years is -$7.3 million, with a median of -$10.0 million recorded in 2023.
- The sharpest annual moves came in 2023 and 2025: Net Income soared 417.8% in 2023, then tumbled 839.69% in 2025.
- Over 5 years, Net Income stood at $9.8 million in 2022, then sank by 213.2% to -$11.1 million in 2023, then jumped by 71.32% to -$3.2 million in 2024, then sank by 839.69% to -$29.8 million in 2025, then rose by 27.68% to -$21.6 million in 2026.
- The last three Net Income figures came in at -$21.6 million (Q1 2026), -$29.8 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | -21.56 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -21.56 Mn |
| Dec 31, 2025 | -29.81 Mn |
| Sep 30, 2025 | -3.64 Mn |
| Jun 30, 2025 | -2.69 Mn |
| Mar 31, 2025 | -2.57 Mn |
| Dec 31, 2024 | -3.17 Mn |
| Sep 30, 2024 | -8.00 Mn |
| Jun 30, 2024 | -18.37 Mn |
| Mar 31, 2024 | -9.12 Mn |
| Dec 31, 2023 | -11.06 Mn |
| Sep 30, 2023 | 56.38 Mn |
| Jun 30, 2023 | -10.02 Mn |
| Mar 31, 2023 | -15.43 Mn |
| Dec 31, 2022 | 9.77 Mn |
| Sep 30, 2022 | -17.74 Mn |
| Jun 30, 2022 | -15.99 Mn |
| Mar 31, 2022 | -21.50 Mn |
| Dec 31, 2021 | -17.61 Mn |
| Sep 30, 2021 | -20.10 Mn |
| Jun 30, 2021 | -15.46 Mn |